[{"Abstract":"There is no abstract associated with this presentation.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null}],"Activity":"Chairperson","AdditionalFields":[{"Key":"Topics","Value":",,"},{"Key":"Keywords","Value":",,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":null,"AttendeeRatingAvg":null,"AttendeeRatingCount":null,"AuthorBlock":"<presenter><u><i>Ryan B. Corcoran<\/i><\/u><\/presenter>. Massachusetts General Hospital, Weston, MA","CSlideId":"","ControlKey":"65725483-a4c6-4028-b59c-4bf8902d63b1","ControlNumber":"12072","DisclosureBlock":"&nbsp;<b>&nbsp;R.B. Corcoran:<\/b>  ; Alterome Therapeutics. ; Asana Biosciences. ; Avidity Biosciences. ; C4 Therapeutics. ; Cogent Biosciences. ; Eli Lilly and Company. ; Erasca. ; FOG pharma. ; Guardant Health. ; Interline Therapeutics. ; Kinnate Biopharma. ; Mirati Therapeutics. ; Nested Therapeutics. ; Novartis. ; Pfizer. ; Qiagen, LLC. ; Remix Therapeutics. ; Revolution Medicines. ; Taiho Pharmaceutical. ; Theonys. ; nRichDx.","End":"4\/8\/2024 10:16:00 AM","HasWebcast":null,"Highlights":[],"Id":"11767","IsPresentation":"False","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":"cslide-player-enabled is not true","PositionInSession":"1","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"","PresenterBiography":null,"PresenterDisplayName":"Ryan Corcoran, MD;PhD","PresenterKey":"7449f103-e67f-4251-acda-d5bf87f198e5","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"Chair","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024 10:15AM","SessionId":"661","SessionOnDemand":"False","SessionTitle":"Advances in Targeted Therapy","ShowChatLink":"false","Start":"4\/8\/2024 10:15:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Chair","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++PL06-01 Phase III adult clinical trials,,"},{"Key":"Keywords","Value":"Breast cancer,BRCA,PARP inhibitors,Chemotherapy response,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":null,"AttendeeRatingAvg":null,"AttendeeRatingCount":null,"AuthorBlock":"<b>J. E. Abraham<\/b><sup>1<\/sup>, L. Oplustil O’Connor<sup>2<\/sup>, A. Dayimu<sup>3<\/sup>, L. Grybowicz<sup>3<\/sup>, K. Pinilla<sup>1<\/sup>, N. Demiris<sup>3<\/sup>, C. Harvey<sup>3<\/sup>, L. M. Drewett<sup>1<\/sup>, R. Lucey<sup>1<\/sup>, A. Fulton<sup>1<\/sup>, A. N. Roberts<sup>3<\/sup>, J. Brown<sup>2<\/sup>, J. R. Worley<sup>1<\/sup>, A. Chhabra<sup>3<\/sup>, R. M. Hardy<sup>3<\/sup>, A. Borley<sup>4<\/sup>, J. P. Braybrooke<sup>5<\/sup>, M. Moody<sup>6<\/sup>, M. B. Mukesh<sup>7<\/sup>, M. Churn<sup>8<\/sup>, S. Raj<sup>9<\/sup>, E. Staples<sup>10<\/sup>, R. R. Roylance<sup>11<\/sup>, S. Chan<sup>12<\/sup>, K. McAdam<sup>13<\/sup>, N. Levitt<sup>14<\/sup>, A. C. Armstrong<sup>15<\/sup>, E. R. Copson<sup>16<\/sup>, P. Wijnhoven<sup>2<\/sup>, P. Schouten<sup>17<\/sup>, E. McMurtry<sup>18<\/sup>, M. Tischkowitz<sup>19<\/sup>, E. Provenzano<sup>17<\/sup>, M. J. O'Connor<sup>2<\/sup>, H. Earl<sup>1<\/sup>, PARTNER Trial Group; <br\/><sup>1<\/sup>Precision Breast Cancer Institute, Dept of Oncology, University of Cambridge, Cambridge, United Kingdom, <sup>2<\/sup>AstraZeneca, Cambridge, United Kingdom, <sup>3<\/sup>Cambridge University Hospital NHS Foundation Trust, Cambridge, United Kingdom, <sup>4<\/sup>Velindre Cancer Centre,, Cardiff, United Kingdom, <sup>5<\/sup>University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, United Kingdom, <sup>6<\/sup>West Suffolk Hospital NHS Foundation Trust, Bury St Edmunds, United Kingdom, <sup>7<\/sup>Colchester General Hospital, East Suffolk & North Essex NHS Trust, Colchester, United Kingdom, <sup>8<\/sup>Worcestershire Acute Hospitals NHS Trust, Worcester, United Kingdom, <sup>9<\/sup>University Hospitals Southampton Foundation Trust, Southampton, United Kingdom, <sup>10<\/sup>Queen's Hospital, Barking, Havering and Redbridge University Hospitals NHS Trust, Romford, United Kingdom, <sup>11<\/sup>University College London Hospitals NHS Foundation Trust,, London, United Kingdom, <sup>12<\/sup>The City Hospital, Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom, <sup>13<\/sup>Peterborough City Hospital, North West Anglia NHS Foundation Trust, Peterborough, United Kingdom, <sup>14<\/sup>Oxford University Hospital NHS Foundation Trust, Oxford, United Kingdom, <sup>15<\/sup>The Christie NHS Foundation Trust, Manchester, United Kingdom, <sup>16<\/sup>University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom, <sup>17<\/sup>Cambridge University Hospitals NHS Foundation Trust, Cambridge, Cambridge, United Kingdom, <sup>18<\/sup>EMC2 Clinical Consultancy Ltd, Sale, Greater Manchester, United Kingdom, <sup>19<\/sup>Department of Medical Genetics, National Institute for Health Research, Cambridge Biomedical Research Centre, University of Cambridge, Cambridge, United Kingdom","CSlideId":"","ControlKey":"b1ba7b2e-ba59-4950-a83b-1c5a64ce58c8","ControlNumber":"10360","DisclosureBlock":"<b>&nbsp;J. E. Abraham, <\/b> <br><b>AstraZeneca<\/b> Grant\/Contract, Travel, Other, Advisory capacity, honoraria. <br><b>Esai<\/b> Other, Honoraria for lecture. <br><b>Pfizer<\/b> Other, Honoraria for lecture. <br><b>L. Oplustil O’Connor, <\/b> <br><b>AstraZeneca<\/b> Employment, Stock.<br><b>A. Dayimu, <\/b> None..<br><b>L. Grybowicz, <\/b> None..<br><b>K. Pinilla, <\/b> None..<br><b>N. Demiris, <\/b> None..<br><b>C. Harvey, <\/b> None..<br><b>L. M. Drewett, <\/b> None..<br><b>R. Lucey, <\/b> None..<br><b>A. Fulton, <\/b> None..<br><b>A. N. Roberts, <\/b> None.&nbsp;<br><b>J. Brown, <\/b> <br><b>AstraZeneca<\/b> Employment, Stock.<br><b>J. R. Worley, <\/b> None..<br><b>A. Chhabra, <\/b> None..<br><b>R. M. Hardy, <\/b> None..<br><b>A. Borley, <\/b> None..<br><b>J. P. Braybrooke, <\/b> None..<br><b>M. Moody, <\/b> None.&nbsp;<br><b>M. B. Mukesh, <\/b> <br><b>Roche<\/b> Other, Advisory Board, speaker fees, meeting expenses. <br><b>Pfizer<\/b> Other, Advisory Board, speaker fees. <br><b>MSD<\/b> Other, Advisory Board, speaker fees, meeting expenses. <br><b>Daiichi - Sankyo<\/b> Other, Advisory Board, speaker fees. <br><b>Gilead<\/b> Other, Advisory Board. <br><b>AstraZeneca<\/b> Other, Advisory Board, speaker fees. <br><b>Novartis<\/b> Other, Advisory Board, speaker fees, meeting expenses. <br><b>Menarini Group<\/b> Other, Advisory Board. <br><b>Genomic Health (Precision Medicine)<\/b> Other, Advisory Board, speaker fees. <br><b>Seagen<\/b> Other, Advisory Board, speaker fees. <br><b>BMS<\/b> Other, Speaker fees. <br><b>Eli Lilly<\/b> Other, Speaker fees, meeting expenses. <br><b>Eisai<\/b> Speaker.<br><b>M. Churn, <\/b> None..<br><b>S. Raj, <\/b> None..<br><b>E. Staples, <\/b> None..<br><b>R. R. Roylance, <\/b> None..<br><b>S. Chan, <\/b> None..<br><b>K. McAdam, <\/b> None.&nbsp;<br><b>N. Levitt, <\/b> <br><b>AstraZeneca<\/b> Stock. <br><b>A. C. Armstrong, <\/b> <br><b>AstraZeneca<\/b> Grant\/Contract, Other, Advisory board. <br><b>Roche<\/b> Travel, Other, Conference fees, advisory board. <br><b>Novartis<\/b> Other, Conference fees. <br><b>MSD<\/b> Other, Conference fees. <br><b>Gilead<\/b> Grant\/Contract. <br><b>E. R. Copson, <\/b> <br><b>AstraZeneca<\/b> Grant\/Contract, Honorarium, advisory board. <br><b>Eli Lilly<\/b> Other, Honorarium, advisory board. <br><b>Novartis<\/b> Other, Honorarium, advisory board.. <br><b>Pfizer<\/b> Other, Honorarium, advisory board, consultancy. <br><b>Roche<\/b> Other, Honorarium. <br><b>Menarini Stemline UK<\/b> Other, Advisory board. <br><b>Daiichi Sankyo<\/b> Grant\/Contract. <br><b>SECA<\/b> Grant\/Contract. <br><b>P. Wijnhoven, <\/b> <br><b>AstraZeneca<\/b> Employment, Stock. <br><b>P. Schouten, <\/b> <br><b>AstraZeneca<\/b> Other, Partner is employed by AstraZeneca..<br><b>E. McMurtry, <\/b> None..<br><b>M. Tischkowitz, <\/b> None.&nbsp;<br><b>E. Provenzano, <\/b> <br><b>Roche<\/b> Other, Honoraria. <br><b>Novartis<\/b> Other, Honoraria. <br><b>AstraZeneca<\/b> Other, Honoraria. <br><b>M. J. O'Connor, <\/b> <br><b>AstraZeneca<\/b> Employment, Stock.<br><b>H. Earl, <\/b> None.","End":"4\/8\/2024 10:30:00 AM","HasWebcast":null,"Highlights":[],"Id":"11427","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"2","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT011","PresenterBiography":null,"PresenterDisplayName":"Jean Abraham, MBChB","PresenterKey":"48c32ee2-00ea-4f2e-b060-afed69a5a68a","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT011. The PARTNER trial: Neoadjuvant olaparib in germline BRCA mutated breast cancer (gBRCA); \"gap\"&#8217; scheduling with carboplatin and paclitaxel, a step closer to cure","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024 10:15AM","SessionId":"661","SessionOnDemand":"False","SessionTitle":"Advances in Targeted Therapy","ShowChatLink":"false","Start":"4\/8\/2024 10:15:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"The PARTNER trial: Neoadjuvant olaparib in germline BRCA mutated breast cancer (gBRCA); \"gap\"&#8217; scheduling with carboplatin and paclitaxel, a step closer to cure","Topics":null,"cSlideId":""},{"Abstract":"<b>Background:<\/b> TNBCs in patients (pts) who are germline BRCA wild type (gBRCAwt) may show homologous recombination deficiency and genomic instability, resulting in a BRCA-like phenotype. The PARTNER Trial tested olaparib in combination with neoadjuvant carboplatin and paclitaxel in pts with TNBC (gBRCAwt). <b>Methods:<\/b> Pts with TNBC diagnosed locally were confirmed centrally with immunohistochemistry for ER, PR, HER2 and EGFR, CK5\/6 and AR to define basal-like TNBC, before entry to the PARTNER trial. Pts were gBRCAwt. Tumours were assessed for tumour infiltrating lymphocytes (TILs). Pts were randomised 1:1 to research (R) and control arms (C). Pts received neoadjuvant carboplatin AUC 5, day(d) 1, with paclitaxel 80mg\/m<sup>2<\/sup> d1, 8, 15, every (q) 3 weeks (w), x 4 cycles(cy), +\/- olaparib 150mg bd, po, d3-14 q 3w. Then all pts had 3cy of anthracycline chemotherapy before surgery. Primary endpoint was pathological complete response (pCR), and secondary endpoints included event-free survival (EFS), and overall survival (OS). A total of 454 patients were needed to attest 90% power with 5% significance assuming pCR rate of 50% in C and 65% in R. <b>Results:<\/b> From Sept 2016 to Dec 2021, 559 pts with TNBC (gBRCAwt) were randomised at 29 UK centres. Data cut-off was 30\/11\/23 with median (med) follow-up of 38 months (m). There were 276 R and 264 C pts in the intention-to-treat population. Pt and tumour characteristics were balanced between the arms: med pt age 49 years; 95% ECOG 0; 36% previous oophorectomy or post-menopausal; 95% tumour size &#8804;50mm; TILS score &#8805;60% in 22%. In R, 88% received at least 80% of the planned olaparib dose. More than 90% of patients in both R and C received at least 80% of the planned carboplatin (R 96% and C 94%) and paclitaxel (R 100% and C 99%) doses.Of 543 pts, 141 (51.1%) in R and 140 (52.4%) in C had a pCR with a difference of -1.3% (95% CI -9.7% to 7.0%, p-value=0.753). Percentage of pts with pCR increased with increasing TILs; pCR rate was 32% with TILs 0-10%, increasing to 67% with TILs 90-100%. Estimated EFS at 36 months (m) was 80% in R and 79% in C (log-rank p&#62;0.9); estimated OS at 36m was 90% in R and 87.2% in C (log-rank p=0.8). Estimated 36m EFS rate was 90.4% (95% CI, 86.4 to 94.5) in pts with pCR and 70% (95% CI, 64.2 to 76.2) in pts with non-pCR (HR=0.3, 95% CI 0.2 to 0.4; p &#60; 0.001). Estimated 36m OS was 95.7% (95% CI, 93.0 to 98.5) in pts with pCR, and 83% (95% CI, 78 to 88.2) in pts with non-pCR (HR=0.2, 95% CI 0.1 to 0.3; p &#60; 0.001). More events and deaths were observed in non-pCR pts compared to pCR pts regardless of the treatment received. <b>Conclusions:<\/b> Neo-adjuvant olaparib in the dose and schedule tested, in addition to carboplatin\/taxol and anthracycline chemotherapy in basal-like TNBC in gBRCAwt patients, did not improve pCR rates, EFS or OS. Pts who achieved a pCR had significantly better EFS and OS than those with non-pCR. These results are in marked contrast to the significant benefit of olaparib in those with gBRCA mutations reported in parallel.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++PL06-01 Phase III adult clinical trials,,"},{"Key":"Keywords","Value":"Breast cancer,Triple-negative breast cancer (TNBC),PARP inhibitors,Chemotherapy response,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":null,"AttendeeRatingAvg":null,"AttendeeRatingCount":null,"AuthorBlock":"J. E. Abraham<sup>1<\/sup>, <b>K. Pinilla<\/b><sup>1<\/sup>, L. Grybowicz<sup>2<\/sup>, A. Dayimu<sup>2<\/sup>, N. Demiris<sup>2<\/sup>, C. Harvey<sup>2<\/sup>, L. M. Drewett<sup>3<\/sup>, R. Lucey<sup>1<\/sup>, A. Fulton<sup>1<\/sup>, A. N. Roberts<sup>2<\/sup>, J. R. Worley<sup>1<\/sup>, A. Chhabra<sup>2<\/sup>, W. Qian<sup>2<\/sup>, R. M. Hardy<sup>2<\/sup>, S. Chan<sup>4<\/sup>, T. Hickish<sup>5<\/sup>, D. Tripathi<sup>6<\/sup>, R. Venkitaraman<sup>7<\/sup>, M. Persic<sup>8<\/sup>, S. Aslam<sup>9<\/sup>, D. Glassman<sup>10<\/sup>, S. Raj<sup>11<\/sup>, A. Borley<sup>12<\/sup>, J. P. Braybrooke<sup>13<\/sup>, S. Sutherland<sup>14<\/sup>, E. Staples<sup>15<\/sup>, L. C. Scott<sup>16<\/sup>, M. Davies<sup>17<\/sup>, C. A. Palmer<sup>18<\/sup>, M. Moody<sup>19<\/sup>, M. J. Churn<sup>20<\/sup>, J. C. Newby<sup>21<\/sup>, M. B. Mukesh<sup>22<\/sup>, A. Chakrabarti<sup>23<\/sup>, R. R. Roylance<sup>24<\/sup>, P. C. Schouten<sup>2<\/sup>, N. Levitt<sup>25<\/sup>, K. McAdam<sup>26<\/sup>, A. C. Armstrong<sup>27<\/sup>, E. R. Copson<sup>28<\/sup>, E. McMurtry<sup>29<\/sup>, M. Tischkowitz<sup>30<\/sup>, E. Provenzano<sup>2<\/sup>, H. Earl<sup>1<\/sup>, PARTNER Trial Group; <br\/><sup>1<\/sup>Precision Breast Cancer Institute, Dept of Oncology, University of Cambridge, Cambridge, United Kingdom, <sup>2<\/sup>Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom, <sup>3<\/sup>Royal Devon University Healthcare NHS Foundation Trust, Exeter, United Kingdom, <sup>4<\/sup>The City Hospital, Nottingham University Hospitals NHS Trust, Cambridge, United Kingdom, <sup>5<\/sup>Royal Bournemouth General Hospital, Bournemouth, United Kingdom, <sup>6<\/sup>Royal Wolverhampton NHS Trust, Wolverhampton, United Kingdom, <sup>7<\/sup>Ipswich Hospital, East Suffolk and North Essex NHS Foundation Trust, Ipswich, United Kingdom, <sup>8<\/sup>University Hospitals of Derby and Burton NHS Foundation Trust, Derby, United Kingdom, <sup>9<\/sup>Bedford Hospital, Bedfordshire Hospitals NHS Foundation Trust, Bedford, United Kingdom, <sup>10<\/sup>The Mid Yorkshire Hospitals NHS Trust, Wakefield, United Kingdom, <sup>11<\/sup>University Hospitals Southampton Foundation Trust, Southampton, United Kingdom, <sup>12<\/sup>Velindre Cancer Centre, Cardiff, United Kingdom, <sup>13<\/sup>University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, United Kingdom, <sup>14<\/sup>Mount Vernon Cancer Centre, Northwood, United Kingdom, <sup>15<\/sup>Queen's Hospital, Barking, Havering and Redbridge University Hospitals NHS Trust, Romford, United Kingdom, <sup>16<\/sup>Beatson West Of Scotland Cancer Centre, Glasgow, United Kingdom, <sup>17<\/sup>Swansea Bay University Health Board, Swansea, United Kingdom, <sup>18<\/sup>Hinchingbrooke Hospital, North West Anglia NHS Foundation Trust, Huntingdon, United Kingdom, <sup>19<\/sup>West Suffolk Hospital NHS Foundation Trust, Bury St Edmunds, United Kingdom, <sup>20<\/sup>Worcestershire Acute Hospitals NHS Trust, Worcester, United Kingdom, <sup>21<\/sup>Royal Free London NHS Foundation Trust, London, United Kingdom, <sup>22<\/sup>Colchester General Hospital, East Suffolk & North Essex NHS Trust, Colchester, United Kingdom, <sup>23<\/sup>Poole Hospital, University Hospitals Dorset NHS Foundation Trust, Dorset, United Kingdom, <sup>24<\/sup>University College London Hospitals NHS Foundation Trust, London, United Kingdom, <sup>25<\/sup>Oxford University Hospital NHS Foundation Trust, Oxford, United Kingdom, <sup>26<\/sup>Peterborough City Hospital, North West Anglia NHS Foundation Trust, Peterborough, United Kingdom, <sup>27<\/sup>The Christie NHS Foundation Trust, Manchester, United Kingdom, <sup>28<\/sup>University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom, <sup>29<\/sup>EMC2 Clinical Consultancy Ltd, Sale, Greater Manchester, United Kingdom, <sup>30<\/sup>Department of Medical Genetics, National Institute for Health Research, Cambridge Biomedical Research Centre, University of Cambridge, Cambridge, United Kingdom","CSlideId":"","ControlKey":"abaaad0b-21c2-476d-aaed-eb513a35170e","ControlNumber":"10566","DisclosureBlock":"<b>&nbsp;J. E. Abraham, <\/b> <br><b>AstraZeneca<\/b> Grant\/Contract, Travel, Other, Advisory capacity, honoraria. <br><b>Esai<\/b> Other, Honoraria for lecture. <br><b>Pfizer<\/b> Other, Honoraria for lecture.<br><b>K. Pinilla, <\/b> None..<br><b>L. Grybowicz, <\/b> None..<br><b>A. Dayimu, <\/b> None..<br><b>N. Demiris, <\/b> None..<br><b>C. Harvey, <\/b> None..<br><b>L. M. Drewett, <\/b> None..<br><b>R. Lucey, <\/b> None..<br><b>A. Fulton, <\/b> None..<br><b>A. N. Roberts, <\/b> None..<br><b>J. R. Worley, <\/b> None..<br><b>A. Chhabra, <\/b> None..<br><b>W. Qian, <\/b> None..<br><b>R. M. Hardy, <\/b> None..<br><b>S. Chan, <\/b> None..<br><b>T. Hickish, <\/b> None..<br><b>D. Tripathi, <\/b> None..<br><b>R. Venkitaraman, <\/b> None..<br><b>M. Persic, <\/b> None..<br><b>S. Aslam, <\/b> None..<br><b>D. Glassman, <\/b> None..<br><b>S. Raj, <\/b> None..<br><b>A. Borley, <\/b> None..<br><b>J. P. Braybrooke, <\/b> None..<br><b>S. Sutherland, <\/b> None..<br><b>E. Staples, <\/b> None..<br><b>L. C. Scott, <\/b> None..<br><b>M. Davies, <\/b> None..<br><b>C. A. Palmer, <\/b> None.&nbsp;<br><b>M. Moody, <\/b> <br><b>AstrazENECA<\/b> Stock.<br><b>M. J. Churn, <\/b> None..<br><b>J. C. Newby, <\/b> None.&nbsp;<br><b>M. B. Mukesh, <\/b> <br><b>Roche<\/b> Other, Advisory Board, speaker fees, meeting expenses. <br><b>Pfizer<\/b> Other, Advisory Board, speaker fees. <br><b>MSD<\/b> Other, Advisory Board, speaker fees, meeting expenses. <br><b>Daiichi - Sankyo<\/b> Other, Advisory Board, speaker fees. <br><b>Gilead<\/b> Other, Advisory Board. <br><b>AstraZeneca<\/b> Other, Advisory Board, speaker fees. <br><b>Novartis<\/b> Other, Advisory Board, speaker fees, meeting expenses. <br><b>Menarini group<\/b> Other, Advisory Board. <br><b>Genomic Health (Precision Medicine)<\/b> Other, Advisory Board, speaker fees. <br><b>Seagen<\/b> Other, Advisory Board, speaker fees. <br><b>BMS<\/b> Other, Speaker fees. <br><b>Lilly<\/b> Other, Speaker fees, meeting expenses. <br><b>Eisai<\/b> Other, Speaker fees.<br><b>A. Chakrabarti, <\/b> None.&nbsp;<br><b>R. R. Roylance, <\/b> <br><b>Daiichi - Sankyo<\/b> Other, Honoraria, advisory board. <br><b>AstraZeneca<\/b> Other, Honoraria, advisory board. <br><b>Novartis<\/b> Honoraria. <br><b>Pfizer<\/b> Travel, Other, Honoraria, advisory board. <br><b>Eli Lilly<\/b> Other, Advisory board. <br><b>BMS<\/b> Travel. <br><b>Roche<\/b> Travel. <br><b>P. C. Schouten, <\/b> <br><b>AstraZeneca<\/b> Other, Partner is employed by AstraZeneca. <br><b>N. Levitt, <\/b> <br><b>AstraZeneca<\/b> Stock.<br><b>K. McAdam, <\/b> None.&nbsp;<br><b>A. C. Armstrong, <\/b> <br><b>AstraZeneca<\/b> Grant\/Contract, Other, Advisory board. <br><b>Roche<\/b> Travel, Other, Conference fees, advisory board. <br><b>Novartis<\/b> Travel, Conference fees. <br><b>MSD<\/b> Other, Conference fees. <br><b>Gilead<\/b> Grant\/Contract. <br><b>E. R. Copson, <\/b> <br><b>AstraZeneca<\/b> Grant\/Contract, Other, Honorarium, advisory board. <br><b>Eli Lilly<\/b> Other, Honorarium, advisory board. <br><b>Novartis<\/b> Travel, Other, Honorarium, advisory board. <br><b>Pfizer<\/b> Other, Honorarium, advisory board, consultancy. <br><b>Roche<\/b> Travel, Other, Honorarium. <br><b>Menarini Stemline UK<\/b> Other, Advisory board. <br><b>Daiichi 0 Sankyo<\/b> Grant\/Contract. <br><b>SECA<\/b> Grant\/Contract.<br><b>E. McMurtry, <\/b> None..<br><b>M. Tischkowitz, <\/b> None.&nbsp;<br><b>E. Provenzano, <\/b> <br><b>Roche<\/b> Other, Honoraria. <br><b>Novartis<\/b> Other, Honoraria. <br><b>AstraZeneca<\/b> Honoraria.<br><b>H. Earl, <\/b> None.","End":"4\/8\/2024 10:45:00 AM","HasWebcast":null,"Highlights":[],"Id":"11428","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":"cslide-player-enabled is not true","PositionInSession":"3","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT012","PresenterBiography":null,"PresenterDisplayName":"Karen Pinilla, MD","PresenterKey":"0d3bd6d3-148f-4d15-b6fb-429f47553e07","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT012. PARTNER Trial: Neoadjuvant olaparib in triple negative breast cancer (TNBC)","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024 10:15AM","SessionId":"661","SessionOnDemand":"False","SessionTitle":"Advances in Targeted Therapy","ShowChatLink":"false","Start":"4\/8\/2024 10:30:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"PARTNER Trial: Neoadjuvant olaparib in triple negative breast cancer (TNBC)","Topics":null,"cSlideId":""},{"Abstract":"There is no abstract associated with this presentation.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null}],"Activity":"Invited Speaker","AdditionalFields":[{"Key":"Topics","Value":",,"},{"Key":"Keywords","Value":",,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":null,"AttendeeRatingAvg":null,"AttendeeRatingCount":null,"AuthorBlock":"<presenter><u><i>Hope S. Rugo<\/i><\/u><\/presenter>. UCSF Helen Diller Family Comprehensive Cancer Ctr., San Francisco, CA","CSlideId":"","ControlKey":"b64ec9c2-5e61-49b2-800d-aa51d1daa9a6","ControlNumber":"12310","DisclosureBlock":"<b>&nbsp;H. S. Rugo, <\/b> <br><b>AMBRX<\/b> G. <br><b>AstraZeneca<\/b> G. <br><b>Daiichi Sankyo Company<\/b> I, G. <br><b>EISAI INC.<\/b> I. <br><b>Eli Lilly and Company<\/b> G. <br><b>Genentech USA, Inc.<\/b> G. <br><b>Gilead Sciences Inc<\/b> G. <br><b>Hoffman-LaRoche<\/b> G. <br><b>Merck<\/b> G. <br><b>Mylan\/Viatris<\/b> I. <br><b>Napo Pharmaceuticals Inc<\/b> I. <br><b>Novartis<\/b> G. <br><b>OBI Pharma<\/b> G. <br><b>Pfizer<\/b> G. <br><b>Stemline Therapeutics Inc.<\/b> G.","End":"4\/8\/2024 11:00:00 AM","HasWebcast":null,"Highlights":[],"Id":"12010","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":"cslide-player-enabled is not true","PositionInSession":"4","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"","PresenterBiography":null,"PresenterDisplayName":"Hope Rugo, MD","PresenterKey":"3145b893-ce31-42c5-9410-95c0131985a1","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"Discussant","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024 10:15AM","SessionId":"661","SessionOnDemand":"False","SessionTitle":"Advances in Targeted Therapy","ShowChatLink":"false","Start":"4\/8\/2024 10:45:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Discussant","Topics":null,"cSlideId":""},{"Abstract":"There is no abstract associated with this presentation.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null}],"Activity":"Other","AdditionalFields":[{"Key":"Topics","Value":",,"},{"Key":"Keywords","Value":",,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":null,"AttendeeRatingAvg":null,"AttendeeRatingCount":null,"AuthorBlock":". ","CSlideId":"","ControlKey":"91ed929d-9089-4bff-8ca9-999fcde13ed0","ControlNumber":"12137","DisclosureBlock":"","End":"4\/8\/2024 11:10:00 AM","HasWebcast":null,"Highlights":[],"Id":"11836","IsPresentation":"False","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":"cslide-player-enabled is not true","PositionInSession":"5","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"","PresenterBiography":null,"PresenterDisplayName":null,"PresenterKey":null,"PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"Discussion","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024 10:15AM","SessionId":"661","SessionOnDemand":"False","SessionTitle":"Advances in Targeted Therapy","ShowChatLink":"false","Start":"4\/8\/2024 11:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Discussion","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT05-01 Phase II adult clinical trials,,"},{"Key":"Keywords","Value":"Colorectal cancer,KRAS,Targeted therapy,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":null,"AttendeeRatingAvg":null,"AttendeeRatingCount":null,"AuthorBlock":"<b>S. Kopetz<\/b><sup>1<\/sup>, N. V. Uboha<sup>2<\/sup>, S. J. Klempner<sup>3<\/sup>, T. S. Bekaii-Saab<sup>4<\/sup>, J. K. Sabari<sup>5<\/sup>, M. Barve<sup>6<\/sup>, J. N. Saltzman<sup>7<\/sup>, J. Peguero<sup>8<\/sup>, S. Paulson<sup>9<\/sup>, P. A. Jänne<sup>10<\/sup>, M. S. Pelster<sup>11<\/sup>, M. Cruz-Correa<sup>12<\/sup>, K. Velastegui<sup>13<\/sup>, X. Yan<sup>13<\/sup>, H. Der-Torossian<sup>13<\/sup>, R. Yaeger<sup>14<\/sup>; <br\/><sup>1<\/sup>The University of Texas MD Anderson Cancer Center, Houston, TX, <sup>2<\/sup>University of Wisconsin, Madison, WI, <sup>3<\/sup>Massachusetts General Cancer Center, Boston, MA, <sup>4<\/sup>Mayo Clinic, Scottsdale, AZ, <sup>5<\/sup>Perlmutter Cancer Center, New York University Langone Health, New York, NY, <sup>6<\/sup>Mary Crowley Cancer Research Center, Dallas, TX, <sup>7<\/sup>Cleveland Clinic, Cleveland, OH, <sup>8<\/sup>Oncology Consultants PA, Houston, TX, <sup>9<\/sup>Texas Oncology – Baylor Charles A. Sammons Cancer Center, Dallas, TX, <sup>10<\/sup>Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, <sup>11<\/sup>Sarah Cannon Research Institute, Nashville, TN, <sup>12<\/sup>Pan American Center for Oncology Trials, San Juan, PR, <sup>13<\/sup>Mirati Therapeutics, Inc., San Diego, CA, <sup>14<\/sup>Memorial Sloan Kettering Cancer Center, New York, NY","CSlideId":"","ControlKey":"f8a68459-c3b1-4eaf-9b20-3ae34dfd53d1","ControlNumber":"9541","DisclosureBlock":"<b>&nbsp;S. Kopetz, <\/b> <br><b>Lutris, Iylon, Frontier Medicines, Xilis, Navire<\/b> Other Business Ownership, Other, Ownership interests. <br><b>Genentech, EMD Serono, Merck, Holy Stone Healthcare, Novartis, Lilly, Boehringer Ingelheim, AstraZeneca\/MedImmune, Bayer Health, Redx Pharma, Ipsen, HalioDx, Lutris, Jacobio, Pfizer<\/b> Other, Consultant. <br><b>Repare Therapeutics, Inivata, GlaxoSmithKline, Jazz Pharmaceuticals, Iylon, Xilis, Abbvie, Amal Therapeutics, Gilead Sciences, Mirati Therapeutics, Flame Biosciences, Servier, Carina Biotech<\/b> Other, Consultant. <br><b>Bicara Therapeutics, Endeavor BioMedicines, Numab, Johnson & Johnson\/Janssen, Genomic Health, Frontier Medicines, Replimune, Taiho Pharmaceutical, Cardiff Oncology, Ono Pharmaceutical<\/b> Other, Consultant. <br><b>Bristol-Myers Squibb-Medarex, Amgen, Tempus, Foundation Medicine, Harbinger Oncology, Inc, Takeda, CureTeq, Zentalis, Black Stone Therapeutics, NeoGenomics Laboratories<\/b> Other, Consultant. <br><b>Accademia Nazionale Di Medicina, Tachyon Therapeutics<\/b> Other, Consultant. <br><b>Sanofi, Biocartis, Guardant Health, Array BioPharma, Genentech\/Roche, EMD Serono, MedImmune, Novartis, Amgen, Lilly, Daiichi Sankyo<\/b> Grant\/Contract. <br><b>N. V. Uboha, <\/b> <br><b>AstraZeneca, Astellas Pharma, Pfizer, Helsinn Therapeutics, BostonGene, GRAIL, Eisai\/MSD, Bristol Myers Squibb Foundation, Astellas Pharma, Bristol Myers Squibb\/F. Hoffmann-La Roche, Ltd.\/ Ipsen<\/b> Other, Consulting or advisory role. <br><b>Elevation Oncology, Aptitude Health<\/b> Other, Consulting or advisory role. <br><b>EMD Serono, Ipsen<\/b> Grant\/Contract. <br><b>S. J. Klempner, <\/b> <br><b>MBrace Therapeutics<\/b> Stock. <br><b>Leap Therapeutics, Astellas, SU2C-AAR<\/b> Grant\/Contract. <br><b>Astellas, Bristol Myers Squibb, Merck, Eli Lilly, Exact Sciences, Mersana, Pieris, Daiichi Sankyo, AstraZeneca, Novartis, Coherus, Sanofi-Aventis<\/b> Other, Advisory board. <br><b>Leap Therapeutics, Astellas, Arcus<\/b> Other, Principal investigator. <br><b>NCCN, Debbie’s Dream Foundation<\/b> Other, Other. <br><b>T. S. Bekaii-Saab, <\/b> <br><b>Mayo Clinic<\/b> Employment. <br><b>WO\/2018\/183488: HUMAN PD1 PEPTIDE VACCINES AND USES THEREOF – Licensed to Imugene<\/b> Patent. <br><b>WO\/2019\/055687: METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER CACHEXIA – Licensed to Recursion<\/b> Patent. <br><b>Agios, Arcus, Atreca, Boston Biomedical, Bayer, Eisai, Celgene, Eli Lilly, Ipsen, Clovis, Seattle Genetics, Genentech, Novartis, Mirati Therapeutics, Inc., Merus, Abgenomics, Incyte, Pfizer<\/b> Grant\/Contract. <br><b>Bristol Myers Squibb<\/b> Grant\/Contract. <br><b>Ipsen, Arcys, Pfizer, Seattle Genetics, Bayer, Genentech, Incyte, Eisai, Merck, Stemline, Abbvie, Boehringer Ingelheim, Janssen, Daiichi Sankyo, Natera, TreosBio, Celularity, Caladrius Biosciences<\/b> Other, Consulting. <br><b>Exact Science, Sobi, BeiGene, Kanaph, AstraZeneca, Deciphera, MJH Life Sciences, Aptitude Health, Illumina, Foundation Medicine<\/b> Other, Consulting. <br><b>Fibrogen, Suzhou Kintor, AstraZeneca, Exelixis, Merck\/Eisai, PanCan, 1Globe<\/b> Other, IDMC\/DSMB. <br><b>Imugene, Immuneering, Xilis, Replimune Artiva, Sun Biopharma<\/b> Other, Advisory board. <br><b>Uptodate<\/b> Other, Royalties. <br><b>J. K. Sabari, <\/b> <br><b>NYU Langone Health<\/b> Employment. <br><b>Boehringer Ingelheim, Janssen, Mirati Therapeutics, Inc., Regeneron<\/b> Grant\/Contract. <br><b>AstraZeneca, Abbvie, Gilead, Genentech, Janssen, Jazz, Mirati Therapeutics, Inc., Pfizer, Regeneron, Sanofi Genzyme, Takeda<\/b> Other, Consulting fees. <br><b>Medscape, MJHS Onclive, Clinical Care Options<\/b> Other, Payment or honoraria for lectures, presentations, speakers’\u000d\u000abureaus, manuscript writing or educational events. <br><b>M. Barve, <\/b> <br><b>Texas Oncology Physicians Associates<\/b> Stock. <br><b>Mary Crowley Cancer Research<\/b> Grant\/Contract.<br><b>J. N. Saltzman, <\/b> None.&nbsp;<br><b>J. Peguero, <\/b> <br><b>Mirati Therapeutics Inc<\/b> Grant\/Contract. <br><b>S. Paulson, <\/b> <br><b>Actinium<\/b> Stock. <br><b>Cardinal Health, Ideo Oncology<\/b> Other, Invited speaker. <br><b>Incyte, Novartis, Hutchinson<\/b> Other, Writing engagements. <br><b>Amgen, Bristol Myers Squibb, Eisai, Ipsen, AAA, Incyte, Exelixis, Pfizer, QED Therapeutics, Eli Lilly, Mirati Therapeutics, Inc., HutchMED<\/b> Other, Advisory board. <br><b>Ipsen, Novartis, Bristol Myers Squibb, Exelixis, Hutchinson, Taiho, Eli Lilly, AstraZeneca, Incyte, Deciphera, G1 Therapeutics, Zentalis, Neogene, Sotio, Inspirna, Nucana, IGM, Gilead, Camurus, ITM<\/b> Other, Principal investigator. <br><b>Aadi<\/b> Other, Principal investigator. <br><b>P. A. Jänne, <\/b> <br><b>Gatekeeper Pharmaceuticals, Allorion Therapeutics<\/b> Stock. <br><b>AstraZeneca, Daiichi Sankyo, PUMA, Eli Lilly, Boehringer Ingelheim, Revolution Medicines, Takeda Oncology<\/b> Grant\/Contract. <br><b>AstraZeneca, Boehringer Ingelheim, Pfizer, Roche\/Genentech, Chugai Pharmaceuticals, Eli Lilly, Voronoi, Daiichi Sankyo, Biocartis, Novartis, Sanofi, Takeda Oncology, Mirati Therapeutics, Inc.<\/b> Other, Advisory board. <br><b>Transcenta, Silicon Therapeutics, Syndax, Nuvalent, Bayer, Eisai, Allorion Therapeutics, Accutar Biotech, Abbvie, Monte Rosa, Scorpion Therapeutics, Merus, Frontier Medicines, Hongyun Biotechnology<\/b> Other, Advisory board. <br><b>Duality Biologics, Blueprint Medicines<\/b> Other, Advisory board. <br><b>Lab Corp<\/b> Other, Royalties. <br><b>M. S. Pelster, <\/b> <br><b>Actuate Therapeutics, Agenus, Arcus Biosciences, Astellas, BeiGene, BioNTech, Bristol-Myers Squibb, Codiak Biosciences, Compass Therapeutics, CytomX, Eisai, Elevation Oncology, Exelixis, Gilead<\/b> Grant\/Contract. <br><b>Gritstone Oncology, HiberCell, Immune-Onc Therapeutics, Leap Therapeutics, Novartis, OncXerna Therapeutics, Panbela Therapeutics, Revolution Medicines, Surface Oncology, SQZ Biotechnologies<\/b> Grant\/Contract. <br><b>Translational Genomics, TransThera Sciences, ZielBio, 1200 Pharma, Tachyon Therapeutics<\/b> Grant\/Contract. <br><b>Arcus Biosciences, AstraZeneca, Bayer, CytomX, Daiichi Sankyo, EMD Serono, Ipsen Biopharmaceuticals, Jazz Pharmaceuticals, Novartis, Pfizer, SeaGen<\/b> Other, Consulting. <br><b>M. Cruz-Correa, <\/b> <br><b>University of Puerto Rico School of Medicine; Pan American Center for Oncology Trials<\/b> Employment. <br><b>Doctors Hospital San Juan<\/b> Independent Contractor. <br><b>PanAmerican Center for Oncology Trials<\/b> Other Business Ownership. <br><b>MIRATI, Natera, BMS, Merck, BeiGene, Pfizer, Jannsen, SeaGen, Apollomics, Abbvie, HUYABIO, Genentech<\/b> Grant\/Contract. <br><b>Licencing agreement for technology at Johns Hopkins University<\/b> Patent. <br><b>K. Velastegui, <\/b> <br><b>Mirati Therapeutics, Inc.<\/b> Stock. <br><b>Mirati Therapeutics, Inc.<\/b> Employment. <br><b>X. Yan, <\/b> <br><b>Mirati Therapeutics, Inc.<\/b> Employment. <br><b>Mirati Therapeutics, Inc.<\/b> Stock. <br><b>Mirati Therapeutics, Inc.<\/b> Stock Option. <br><b>H. Der-Torossian, <\/b> <br><b>Mirati Therapeutics, Inc.<\/b> Employment. <br><b>Mirati Therapeutics, Inc.<\/b> Stock. <br><b>Mirati Therapeutics, Inc.<\/b> Stock Option. <br><b>Mirati Therapeutics, Inc.<\/b> Patent. <br><b>R. Yaeger, <\/b> <br><b>Pfizer, Boehringer Ingelheim, Mirati Therapeutics, Daiichi Sankyo<\/b> Grant\/Contract. <br><b>Array Biopharma\/Pfizer, Mirati Therapeutics, Inc.<\/b> Other, Advisory board. <br><b>Zai Lab<\/b> Other, Speaker honoraria. <br><b>Amgen<\/b> Travel.","End":"4\/8\/2024 11:25:00 AM","HasWebcast":null,"Highlights":[],"Id":"11429","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"6","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT013","PresenterBiography":null,"PresenterDisplayName":"Rebecca Todd","PresenterKey":"f3a50a29-7b12-4500-aca9-89355ecb15a6","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT013. KRYSTAL-1: Pooled phase 1\/2 efficacy and safety of adagrasib (MRTX849) in combination with cetuximab in patients with metastatic colorectal cancer (CRC) harboring a KRAS<sup>G12C<\/sup> mutation","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024 10:15AM","SessionId":"661","SessionOnDemand":"False","SessionTitle":"Advances in Targeted Therapy","ShowChatLink":"false","Start":"4\/8\/2024 11:10:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"KRYSTAL-1: Pooled phase 1\/2 efficacy and safety of adagrasib (MRTX849) in combination with cetuximab in patients with metastatic colorectal cancer (CRC) harboring a KRAS<sup>G12C<\/sup> mutation","Topics":null,"cSlideId":""},{"Abstract":"There is no abstract associated with this presentation.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null}],"Activity":"Invited Speaker","AdditionalFields":[{"Key":"Topics","Value":",,"},{"Key":"Keywords","Value":",,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":null,"AttendeeRatingAvg":null,"AttendeeRatingCount":null,"AuthorBlock":"<presenter><u><i>Alex A. Adjei<\/i><\/u><\/presenter>. The Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH","CSlideId":"","ControlKey":"d47e7996-a9e0-4ec9-b842-29a0f3c02549","ControlNumber":"12332","DisclosureBlock":"","End":"4\/8\/2024 11:35:00 AM","HasWebcast":null,"Highlights":[],"Id":"12032","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":"cslide-player-enabled is not true","PositionInSession":"7","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"","PresenterBiography":null,"PresenterDisplayName":"Alex Adjei, MD;PhD","PresenterKey":"811b26e4-8bc2-4dca-86d6-91cd28c406b0","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"Discussant","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024 10:15AM","SessionId":"661","SessionOnDemand":"False","SessionTitle":"Advances in Targeted Therapy","ShowChatLink":"false","Start":"4\/8\/2024 11:25:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Discussant","Topics":null,"cSlideId":""},{"Abstract":"There is no abstract associated with this presentation.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null}],"Activity":"Other","AdditionalFields":[{"Key":"Topics","Value":",,"},{"Key":"Keywords","Value":",,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":null,"AttendeeRatingAvg":null,"AttendeeRatingCount":null,"AuthorBlock":". ","CSlideId":"","ControlKey":"70d3e9cd-2d0a-4812-a167-b5a712b687fd","ControlNumber":"12138","DisclosureBlock":"","End":"4\/8\/2024 11:40:00 AM","HasWebcast":null,"Highlights":[],"Id":"11837","IsPresentation":"False","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":"cslide-player-enabled is not true","PositionInSession":"8","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"","PresenterBiography":null,"PresenterDisplayName":null,"PresenterKey":null,"PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"Discussion","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024 10:15AM","SessionId":"661","SessionOnDemand":"False","SessionTitle":"Advances in Targeted Therapy","ShowChatLink":"false","Start":"4\/8\/2024 11:35:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Discussion","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT03-01 First-in-human phase I trials,,"},{"Key":"Keywords","Value":"Solid tumors,Breast cancer,PARP inhibitors,saruparib,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":null,"AttendeeRatingAvg":null,"AttendeeRatingCount":null,"AuthorBlock":"<b>T. A. Yap<\/b><sup>1<\/sup>, A. M. Schram<sup>2<\/sup>, J. Balmaña<sup>3<\/sup>, A. Falcón<sup>4<\/sup>, J. García Corbacho<sup>5<\/sup>, S.-A. Im<sup>6<\/sup>, R. D. Baird<sup>7<\/sup>, J. Wu<sup>8<\/sup>, D. Zou<sup>9<\/sup>, K. Yonemori<sup>10<\/sup>, M. Kim<sup>11<\/sup>, G. Rubovszky<sup>12<\/sup>, G. Moorthy<sup>13<\/sup>, S. Linardopoulos,<sup>14<\/sup>, S. Nanda<sup>15<\/sup>, K. Sugibayashi<sup>14<\/sup>, C. Kennedy<sup>14<\/sup>, J. S. Brown<sup>14<\/sup>, M. Albertella<sup>14<\/sup>, S. Cosulich<sup>14<\/sup>, V. Amezcua<sup>14<\/sup>, E. Lukacs<sup>14<\/sup>, S. J. Luen<sup>16<\/sup>; <br\/><sup>1<\/sup>University of Texas MD Anderson Cancer Center, Houston, TX, <sup>2<\/sup>Memorial Sloan Kettering Cancer Center, New York, NY, <sup>3<\/sup>Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology, Barcelona, Spain, <sup>4<\/sup>Virgen del Rocío University Hospital, Seville, Spain, <sup>5<\/sup>Hospital Virgen de la Victoria, Málaga, Spain, <sup>6<\/sup>Cancer Research Institute, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea, Republic of, <sup>7<\/sup>Addenbrooke’s Hospital, Cambridge, United Kingdom, <sup>8<\/sup>Shanghai Cancer Center, Fudan University, Shanghai, China, <sup>9<\/sup>Chongqing University Cancer Hospital, Chongqing, China, <sup>10<\/sup>National Cancer Center Hospital, Tokyo, Japan, <sup>11<\/sup>Severance Hospital, Seoul, Korea, Republic of, <sup>12<\/sup>National Institute of Oncology, Budapest, Hungary, <sup>13<\/sup>AstraZeneca, Waltham, MA, <sup>14<\/sup>AstraZeneca, Cambridge, United Kingdom, <sup>15<\/sup>AstraZeneca, Gaithersburg, MD, <sup>16<\/sup>Peter MacCallum Cancer Centre, Melbourne, Australia","CSlideId":"","ControlKey":"afe05442-d65b-49aa-a619-8d74ad908f93","ControlNumber":"9882","DisclosureBlock":"<b>&nbsp;T. A. Yap, <\/b> <br><b>MD Anderson Cancer Center<\/b> Employment, Other Intellectual Property, Head of Clinical Development in the Therapeutics Discovery Division at MD Anderson Cancer\u000d\u000aCenter, which has a commercial interest in saruparib and other inhibitors. <br><b>Seagen<\/b> Stock. <br><b>Acrivon;Artios;AstraZeneca;Bayer;BeiGene;BioNTech;Blueprint Bio;Bristol Myers Squibb;Boundless Bio;Clovis;Constellation;Cyteir;Eli Lilly;EMD Serono;Forbius;F-Star;GlaxoSmithKline;Genentech;Haihe<\/b> Grant\/Contract. <br><b>Ideaya Biosciences;ImmuneSensor;Insilico Medicine;Ionis;Ipsen;Jounce;Karyopharm;KSQ;Kyowa;Merck;Mirati;Novartis;Pfizer;Ribon Therapeutics;Regeneron;Repare;Rubius;Sanofi;Scholar Rock;Seattle Genetics;<\/b> Grant\/Contract. <br><b>Tango;Tesaro;Vivace;Zenith<\/b> Grant\/Contract. <br><b>AbbVie;Acrivon;Adagene;Almac;Aduro;Amphista;Artios;Astex;AstraZeneca;Athena;Atrin;Avenzo;Avoro;Axiom;Baptist Health Systems;Bayer;BeiGene;BioCity Biopharma;Blueprint Bio;Boxer Capitol<\/b> Other, Consultancy position. <br><b>Bristol Myers Squibb;C4 Therapeutics;Calithera;Cancer Research UK;Carrick Therapeutics;Circle Pharma;Clovis;Cybrexa;Daiichi Sankyo;Dark Blue Therapeutics;Diffusion;Duke Street Bio;858 Therapeutics<\/b> Other, Consultancy position. <br><b>EcoR1 Capital;Ellipses Pharma;EMD Serono;Entos;F-Star;Genesis Therapeutics;Genmab;Glenmark;GLG Consulting;Globe Life Sciences;GlaxoSmithKline;Guidepoint;Ideaya Biosciences;Idience;Ignyta;I-Mab<\/b> Other, Consultancy position. <br><b>ImmuneSensor;Impact Therapeutics;Institut Gustave Roussy;Intellisphere;Janssen;Kyn;MEI Pharma;Mereo;Merck;Merit;Monte Rosa Therapeutics;Natera;Nested Therapeutics;Nexys;Nimbus;Novocure;<\/b> Other, Consultancy position. <br><b>Odyssey;Oregon Health & Science University;OncoSec;Ono Pharma;PanAngium Therapeutics;Pegascy;PER;Pfizer;Piper-Sandler;Pliant Therapeutics;Prolynx;Radiopharm Theranostics;Repare;resTORbio<\/b> Other, Consultancy position. <br><b>Roche;Ryvu Therapeutics;Swiss Group for Clinical Cancer Research (SAKK);Sanofi;Schrödinger;Servier;Synnovation;Synthis Therapeutics;Tango;TCG Crossover;TD2;Terremoto Biosciences<\/b> Other, Consultancy position. <br><b>Tesselate Bio;Theragnostics;Terns Pharmaceuticals;Tolremo;Tome;Thryv Therapeutics;Trevarx Biomedical;Valerio;Varian;Veeva;Versant;Vibliome;Voronoi Inc;Xinthera;Zai Labs and ZielBio<\/b> Other, Consultancy position. <br><b>A. M. Schram, <\/b> <br><b>AstraZeneca<\/b> Grant\/Contract. <br><b>Beigene\/Springworks<\/b> Grant\/Contract. <br><b>Black Diamond Therapeutics<\/b> Grant\/Contract. <br><b>Elevation Oncology<\/b> Grant\/Contract. <br><b>Eli Lilly<\/b> Grant\/Contract. <br><b>Merus<\/b> Grant\/Contract, Travel, Other, Advisory board. <br><b>Pfizer<\/b> Grant\/Contract. <br><b>PMV Pharma<\/b> Grant\/Contract. <br><b>Relay<\/b> Grant\/Contract, Other, Advisory board. <br><b>Repare Therapeutics<\/b> Grant\/Contract, Other, Advisory board. <br><b>Revolution Medicine<\/b> Grant\/Contract. <br><b>Surface Oncology<\/b> Grant\/Contract. <br><b>Mersana<\/b> Other, Advisory board. <br><b>Schrödinger<\/b> Other, Advisory board. <br><b>Blueprint Bio<\/b> Other, Advisory board. <br><b>Flagship Engineering<\/b> Other, Advisory board. <br><b>Redona Therapeutics<\/b> Other, Advisory board.<br><b>J. Balmaña, <\/b> None.&nbsp;<br><b>A. Falcón, <\/b> <br><b>Novartis<\/b> Other, Speakers bureau. <br><b>Pfizer<\/b> Other, Speakers bureau. <br><b>Eli Lilly<\/b> Other, Speakers bureau. <br><b>Seagen<\/b> Other, Speakers bureau. <br><b>Roche<\/b> Other, Speakers bureau. <br><b>Gilead<\/b> Other, Speakers bureau. <br><b>AstraZeneca<\/b> Other, Speakers bureau. <br><b>Daiichi Sankyo<\/b> Travel, Other, Speakers bureau. <br><b>Eisai<\/b> Other, Speakers bureau. <br><b>Grünenthal<\/b> Other, Speakers bureau.<br><b>J. García Corbacho, <\/b> None.&nbsp;<br><b>S. Im, <\/b> <br><b>AstraZeneca<\/b> Grant\/Contract. <br><b>Boryung Pharmaceutical<\/b> Grant\/Contract. <br><b>Bertis<\/b> Grant\/Contract. <br><b>Daewoong Pharmaceutical<\/b> Grant\/Contract. <br><b>Daiichi Sankyo<\/b> Grant\/Contract. <br><b>Eisai<\/b> Grant\/Contract. <br><b>GlaxoSmithKline<\/b> Grant\/Contract. <br><b>Hanmi<\/b> Grant\/Contract. <br><b>Idience<\/b> Grant\/Contract. <br><b>Eli Lilly,<\/b> Grant\/Contract. <br><b>MSD<\/b> Grant\/Contract. <br><b>Novartis<\/b> Grant\/Contract. <br><b>Pfizer<\/b> Grant\/Contract. <br><b>Roche<\/b> Grant\/Contract. <br><b>R. D. Baird, <\/b> <br><b>AstraZeneca<\/b> Grant\/Contract. <br><b>Carrick Therapeutics<\/b> Grant\/Contract. <br><b>Daiichi Sankyo<\/b> Grant\/Contract. <br><b>G1 Therapeutics<\/b> Grant\/Contract. <br><b>Jannsen<\/b> Grant\/Contract. <br><b>Roche<\/b> Grant\/Contract. <br><b>Taiho<\/b> Grant\/Contract. <br><b>J. Wu, <\/b> <br><b>F. Hoffman La Roche Ltd<\/b> Grant\/Contract. <br><b>AstraZeneca<\/b> Consultant. <br><b>Novartis<\/b> Consultant.<br><b>D. Zou, <\/b> None..<br><b>K. Yonemori, <\/b> None.&nbsp;<br><b>M. Kim, <\/b> <br><b>AstraZeneca<\/b> Grant\/Contract.<br><b>G. Rubovszky, <\/b> None.&nbsp;<br><b>G. Moorthy, <\/b> <br><b>AstraZeneca<\/b> Employment, Stock. <br><b>S. Linardopoulos,, <\/b> <br><b>AstraZeneca<\/b> Employment, Stock. <br><b>S. Nanda, <\/b> <br><b>AstraZeneca<\/b> Employment. <br><b>K. Sugibayashi, <\/b> <br><b>AstraZeneca<\/b> Employment. <br><b>C. Kennedy, <\/b> <br><b>AstraZeneca<\/b> Employment, Stock. <br><b>GlaxoSmithKline<\/b> Stock. <br><b>Amgen<\/b> Stock. <br><b>J. S. Brown, <\/b> <br><b>AstraZeneca<\/b> Employment, Stock. <br><b>M. Albertella, <\/b> <br><b>AstraZeneca<\/b> Employment, Stock. <br><b>S. Cosulich, <\/b> <br><b>AstraZeneca<\/b> Employment. <br><b>V. Amezcua, <\/b> <br><b>AstraZeneca<\/b> Employment, Stock. <br><b>E. Lukacs, <\/b> <br><b>AstraZeneca<\/b> Employment, Stock. <br><b>S. J. Luen, <\/b> <br><b>AstraZeneca<\/b> Other, Research funding. <br><b>Beigene<\/b> Other, Research funding. <br><b>Novartis<\/b> Other, Research funding. <br><b>Roche<\/b> Other, Research funding. <br><b>Springworks Therapeutics<\/b> Other, Research funding.","End":"4\/8\/2024 11:55:00 AM","HasWebcast":null,"Highlights":[],"Id":"11430","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"9","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT014","PresenterBiography":null,"PresenterDisplayName":"Jordan Best","PresenterKey":"09caff0e-0e82-4e63-92a0-4dbc38fa90bc","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT014. PETRA: first-in-human Phase 1\/2a trial of the first-in-class new generation poly(ADP-ribose) polymerase-1 selective inhibitor (PARP1i) saruparib (AZD5305) in patients (pts) with advanced solid tumors with <i>BRCA1\/2<\/i>, <i>PALB2<\/i> or <i>RAD51C\/D<\/i> mutations","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024 10:15AM","SessionId":"661","SessionOnDemand":"False","SessionTitle":"Advances in Targeted Therapy","ShowChatLink":"false","Start":"4\/8\/2024 11:40:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"PETRA: first-in-human Phase 1\/2a trial of the first-in-class new generation poly(ADP-ribose) polymerase-1 selective inhibitor (PARP1i) saruparib (AZD5305) in patients (pts) with advanced solid tumors with <i>BRCA1\/2<\/i>, <i>PALB2<\/i> or <i>RAD51C\/D<\/i> mutations","Topics":null,"cSlideId":""},{"Abstract":"There is no abstract associated with this presentation.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null}],"Activity":"Invited Speaker","AdditionalFields":[{"Key":"Topics","Value":",,"},{"Key":"Keywords","Value":",,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":null,"AttendeeRatingAvg":null,"AttendeeRatingCount":null,"AuthorBlock":"<presenter><u><i>Patricia M. LoRusso<\/i><\/u><\/presenter>. Yale University, New Haven, CT","CSlideId":"","ControlKey":"f27f8acb-c151-4aa3-a97b-2bd321144316","ControlNumber":"12278","DisclosureBlock":"","End":"4\/8\/2024 12:05:00 PM","HasWebcast":null,"Highlights":[],"Id":"11978","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":"cslide-player-enabled is not true","PositionInSession":"10","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"","PresenterBiography":null,"PresenterDisplayName":"Patricia LoRusso, DO;PhD (hc)","PresenterKey":"e04ae404-5217-4b96-8a03-7124c6f46469","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"Discussant","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024 10:15AM","SessionId":"661","SessionOnDemand":"False","SessionTitle":"Advances in Targeted Therapy","ShowChatLink":"false","Start":"4\/8\/2024 11:55:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Discussant","Topics":null,"cSlideId":""},{"Abstract":"There is no abstract associated with this presentation.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null}],"Activity":"Other","AdditionalFields":[{"Key":"Topics","Value":",,"},{"Key":"Keywords","Value":",,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":null,"AttendeeRatingAvg":null,"AttendeeRatingCount":null,"AuthorBlock":". ","CSlideId":"","ControlKey":"9234a930-678b-4a09-9b61-ca50c2234f51","ControlNumber":"12139","DisclosureBlock":"","End":"4\/8\/2024 12:10:00 PM","HasWebcast":null,"Highlights":[],"Id":"11838","IsPresentation":"False","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":"cslide-player-enabled is not true","PositionInSession":"11","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"","PresenterBiography":null,"PresenterDisplayName":null,"PresenterKey":null,"PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"Discussion","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024 10:15AM","SessionId":"661","SessionOnDemand":"False","SessionTitle":"Advances in Targeted Therapy","ShowChatLink":"false","Start":"4\/8\/2024 12:05:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Discussion","Topics":null,"cSlideId":""},{"Abstract":"There is no abstract associated with this presentation.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null}],"Activity":"Other","AdditionalFields":[{"Key":"Topics","Value":",,"},{"Key":"Keywords","Value":",,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":null,"AttendeeRatingAvg":null,"AttendeeRatingCount":null,"AuthorBlock":". ","CSlideId":"","ControlKey":"0ffb4503-4f08-4a41-ab4c-047c2062023f","ControlNumber":"12312","DisclosureBlock":"","End":"4\/8\/2024 12:15:00 PM","HasWebcast":null,"Highlights":[],"Id":"12012","IsPresentation":"False","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":"cslide-player-enabled is not true","PositionInSession":"12","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"","PresenterBiography":null,"PresenterDisplayName":null,"PresenterKey":null,"PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"Closing remarks","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024 10:15AM","SessionId":"661","SessionOnDemand":"False","SessionTitle":"Advances in Targeted Therapy","ShowChatLink":"false","Start":"4\/8\/2024 12:10:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Closing remarks","Topics":null,"cSlideId":""}]